Wiman KG - Search Results

1

Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.

Fransson Å, Glaessgen D, Alfredsson J, Wiman KG, Bajalica-Lagercrantz S, Mohell N. Fransson Å, et al. Among authors: wiman kg. J Ovarian Res. 2016 May 14;9(1):27. doi: 10.1186/s13048-016-0239-6. J Ovarian Res. 2016. PMID: 27179933 Free PMC article.

2

Reactivation of mutant p53: a new strategy for cancer therapy.

Selivanova G, Kawasaki T, Ryabchenko L, Wiman KG. Selivanova G, et al. Among authors: wiman kg. Semin Cancer Biol. 1998;8(5):369-78. doi: 10.1006/scbi.1998.0099. Semin Cancer Biol. 1998. PMID: 10101802 Review.

3

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.

Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, Selivanova G. Bykov VJ, et al. Among authors: wiman kg. Nat Med. 2002 Mar;8(3):282-8. doi: 10.1038/nm0302-282. Nat Med. 2002. PMID: 11875500

4

PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis.

Bykov VJ, Zache N, Stridh H, Westman J, Bergman J, Selivanova G, Wiman KG. Bykov VJ, et al. Among authors: wiman kg. Oncogene. 2005 May 12;24(21):3484-91. doi: 10.1038/sj.onc.1208419. Oncogene. 2005. PMID: 15735745

5

Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs.

Bykov VJ, Issaeva N, Zache N, Shilov A, Hultcrantz M, Bergman J, Selivanova G, Wiman KG. Bykov VJ, et al. Among authors: wiman kg. J Biol Chem. 2005 Aug 26;280(34):30384-91. doi: 10.1074/jbc.M501664200. Epub 2005 Jul 1. J Biol Chem. 2005. PMID: 15998635 Free article.

6

Reactivation of mutant p53: molecular mechanisms and therapeutic potential.

Selivanova G, Wiman KG. Selivanova G, et al. Among authors: wiman kg. Oncogene. 2007 Apr 2;26(15):2243-54. doi: 10.1038/sj.onc.1210295. Oncogene. 2007. PMID: 17401433 Review.

7

Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy.

Wiman KG. Wiman KG. Adv Cancer Res. 2007;97:321-38. doi: 10.1016/S0065-230X(06)97014-6. Adv Cancer Res. 2007. PMID: 17419952 Review.

8

Mutant p53 targeting by the low molecular weight compound STIMA-1.

Zache N, Lambert JM, Rökaeus N, Shen J, Hainaut P, Bergman J, Wiman KG, Bykov VJ. Zache N, et al. Among authors: wiman kg. Mol Oncol. 2008 Jun;2(1):70-80. doi: 10.1016/j.molonc.2008.02.004. Epub 2008 Mar 7. Mol Oncol. 2008. PMID: 19383329 Free PMC article.

9

PRIMA-1 reactivates mutant p53 by covalent binding to the core domain.

Lambert JM, Gorzov P, Veprintsev DB, Söderqvist M, Segerbäck D, Bergman J, Fersht AR, Hainaut P, Wiman KG, Bykov VJ. Lambert JM, et al. Among authors: wiman kg. Cancer Cell. 2009 May 5;15(5):376-88. doi: 10.1016/j.ccr.2009.03.003. Cancer Cell. 2009. PMID: 19411067 Free article.

10

Mutant p53 rescue and modulation of p53 redox state.

Bykov VJ, Lambert JM, Hainaut P, Wiman KG. Bykov VJ, et al. Among authors: wiman kg. Cell Cycle. 2009 Aug 15;8(16):2509-17. doi: 10.4161/cc.8.16.9382. Epub 2009 Aug 29. Cell Cycle. 2009. PMID: 19633417 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

189 results

Search Page